
Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million, resulting in a 107.1% decrease from last quarter. Antares Pharma earned $32.68 million, and sales totaled $48.73 million in Q4.